

Asset Screening

Red flags or reliable returns? See the full picture of pharma asset potential.

Asset screening in pharma and biotech is crucial, complex, and fraught with potential biases. How can your team be sure you are making moves based on a clear, impartial assessment of asset value and potential pitfalls?


With Evaluate, you can objectively determine the true worth of acquisition and licensing targets or your own portfolio. Use extensive risk and return data to forecast product-level risk, costs, and timelines. Make pivotal business decisions with confidence and achieve higher deal value.





ACCURATE ASSET SCREENING TO ANSWER KEY BUSINESS QUESTIONS


Use Evaluate to uncover emerging trends, find assets that strengthen your pipeline, and understand where your drug and asset portfolios stand compared to the competition. Stay ahead of market changes and grasp their impact on both your business and your competitors.



What are the emerging trends?



What does our portfolio of drugs and assets look like?



Are there external assets that would benefit our pipeline?



How do I stay ahead of changes that might impact me or my competitors?

Gain invaluable insights and recommendations to optimise your resources and maximise your performance. Take the next step towards your success.

► THE CHALLENGE

Screening and valuing pharma assets can be a thorny path, given the many complex data points, high failure rates, and ever-present risk of human bias. Use Evaluate to sanity-check your assumptions, conduct deep due diligence, and form an objective picture of the true commercial possibilities.



► HOW WE HELP

Whether you are expanding your product pipeline or entering a new market, Evaluate gives you a clear, impartial view of pharma asset potential.




BENCHMARK INTERNAL FORECASTS WITH CONSENSUS FORECASTS

Create a target list to screen for potential assets and identify candidates for in-licencing and acquisition that fit your specific area. Determine which assets have positive readouts versus those that raise red flags. Cross-check your internal view with the industry's trusted consensus forecast, ensuring all relevant data sources are considered and evaluated.



FOCUS ON SPECIFIC BUSINESS QUESTIONS

Use our NPV Analyzer to track potential assets and project sales, peak revenue times, and costs. Recognise risks, strengths, weaknesses, and areas for improvement so you can form actionable recommendations from the analysis for both internal and external reporting.



BUILD AND INFORM YOUR INVESTMENT STRATEGY

Conduct a detailed market analysis, understand macro trends, compare specific companies, and explore emerging spaces. Search for companies that are ready for funding or acquisition, identify risks, and evaluate potential assets earlier in the screening process with a single view of R&D risk and return.





▶ OUR SOLUTION: EVALUATE FOR ASSET SCREENING

Are you looking to expand your product pipelines, enter new markets, or verify an asset's potential? Equip your commercial team to discover trends, pinpoint opportunities, and stay ahead of the changes impacting your business and competitors.



USE EVALUATE TO:

- ▶ Make accurate predictions of product-level risk, costs, and timelines
- ▶ Benchmark internal forecasts with consensus forecasts
- ▶ Identify candidates for in-licensing and acquisition that fit your specific area
- ▶ Identify projected sales, peak times for revenues, and costs
- ▶ Uncover potential risks, strengths, weaknesses, and opportunities for improvement
- ▶ Evaluate potential assets earlier with a single view of R&D risk and return



PRODUCTS TAILORED TO SUIT YOU

Evaluate
Pharma

Evaluate
Omnium

Evaluate
Epi

Europe Drug
Forecasts

Japan Drug
Forecasts

We're here to help you succeed

Get in touch to discuss how to leverage our best-in-class market data for asset screening.

Evaluate
a norstella company

info@evaluate.com | www.evaluate.com

Evaluate HQ: +44-(0)20-7377-0800 | Evaluate Americas: +1-617-573-9450 | Evaluate APAC: +81-(0)80-1164-4754